Brenda Avelina Lopez Muñiz, Rosa Martha Perez Gutierrez, Alethia Muñiz-Ramirez
{"title":"Starch Biopolymer Functionalized with Ipomoea batatas Extract: A Natural System for Bioactive Delivery in Type II Diabetes.","authors":"Brenda Avelina Lopez Muñiz, Rosa Martha Perez Gutierrez, Alethia Muñiz-Ramirez","doi":"10.2174/0115672018385495250801091747","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Type 2 diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia. Natural compounds derived from plants, such as Ipomoea batatas, have shown therapeutic potential for its treatment.</p><p><strong>Methods: </strong>A starch-based biopolymer was developed and functionalized with a methanolic extract of Ipomoea batatas (IBM). Its physicochemical properties, such as swelling capacity, encapsulation efficiency, and extract release, were evaluated. In vivo tests were conducted on diabetic Danio rerio using two administration routes: immersion and oral delivery.</p><p><strong>Results: </strong>The biopolymer exhibited a swelling capacity of 333.03% and an encapsulation efficiency of 47.78%. In the zebrafish model, significant reductions in glucose, triglycerides, and cholesterol levels were observed, along with inhibition of advanced glycation end products (AGEs) formation in groups treated with IBM and BP-IBM.</p><p><strong>Discussion: </strong>The results suggest that the biopolymer preserves the chemical integrity of the extract and improves its bioavailability, enabling a significant therapeutic effect. The dual administration routes provide flexibility and demonstrate the efficacy of the delivery system.</p><p><strong>Conclusion: </strong>The starch-based system functionalized with I. batatas extract proved to be a promising and non-toxic platform for the delivery of bioactive metabolites in type 2 diabetes models, with potential for future therapeutic applications.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672018385495250801091747","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Type 2 diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia. Natural compounds derived from plants, such as Ipomoea batatas, have shown therapeutic potential for its treatment.
Methods: A starch-based biopolymer was developed and functionalized with a methanolic extract of Ipomoea batatas (IBM). Its physicochemical properties, such as swelling capacity, encapsulation efficiency, and extract release, were evaluated. In vivo tests were conducted on diabetic Danio rerio using two administration routes: immersion and oral delivery.
Results: The biopolymer exhibited a swelling capacity of 333.03% and an encapsulation efficiency of 47.78%. In the zebrafish model, significant reductions in glucose, triglycerides, and cholesterol levels were observed, along with inhibition of advanced glycation end products (AGEs) formation in groups treated with IBM and BP-IBM.
Discussion: The results suggest that the biopolymer preserves the chemical integrity of the extract and improves its bioavailability, enabling a significant therapeutic effect. The dual administration routes provide flexibility and demonstrate the efficacy of the delivery system.
Conclusion: The starch-based system functionalized with I. batatas extract proved to be a promising and non-toxic platform for the delivery of bioactive metabolites in type 2 diabetes models, with potential for future therapeutic applications.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
